Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease (Q34659424)

3 August 2017

1 reference

title

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease (English)

1 reference

3 August 2017

lorcaserin hydrochloride

1 reference

lorcaserin hydrochloride hemihydrate

ChEBI release 2020-05-28

ChEBI ID

65350

1 reference

ChEBI release 2020-05-28

Harold E Bays

1

1 reference

3 August 2017

1 November 2009

1 reference

Expert Review of Cardiovascular Therapy

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

11

1 reference

3 August 2017

1429-1445

1 reference

Assessment of the obese patient

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy: why do adiposity and obesity cause metabolic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Is adiposopathy (sick fat) an endocrine disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adipose tissue dysfunction in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

"Sick fat," metabolic disease, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Metabolic and body composition factors in subgroups of obesity: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Systematic review: an evaluation of major commercial weight loss programs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Clinical trial issues in weight-loss therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Pharmacotherapy of obesity - benefit, bias and hyperbole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Anti-obesity drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Current and investigational antiobesity agents and obesity therapeutic treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Feeding behavior in mammals including humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Central and peripheral regulation of food intake and physical activity: pathways and genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Pharmacological targeting of the serotonergic system for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Feeding and stress interact through the serotonin 2C receptor in developing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Genes within the serotonergic system are differentially expressed in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

5-hydroxytryptamine receptors in the human cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Long-term weight control study: conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adipogenic and antiapoptotic protein levels in human adipose stromal cells after weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Pharmacotherapy to reduce visceral fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Obesity, Metabolic Syndrome, and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The adipocyte as an endocrine cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Adipose tissues as an ancestral immune organ: site-specific change in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Role of adipose tissue as an inflammatory organ in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Fenfluramine-induced immunosuppression: an in vivo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonergic drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Drugs and valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Perioperative safety in the longitudinal assessment of bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Thyroid hormone and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The central melanocortin system directly controls peripheral lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

BDNF regulates eating behavior and locomotor activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Melanin-concentrating hormone activates signaling pathways in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

Dexfenfluramine. Its place in weight control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.123

21 January 2018

Identifiers

DOI

10.1586/ERC.09.123

1 reference

3 August 2017

1 reference

PubMed ID

19900026